SEARCH

SEARCH BY CITATION

References

  • Abou-Samra AB, Catt KJ, Aguilera G (1986). Involvement of protein kinase C in the regulation of adrenocorticotropin release from rat anterior pituitary cells. Endocrinology 118: 212217.
  • Aguilera G, Kiss A, Luo X (1995). Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration. J Neuroendocrinol 7: 775783.
  • Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T et al. (2001). Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276: 4862348626.
  • Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H (2006). Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48: 5157.
  • Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F et al. (2006). Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55: 11591164.
  • Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M et al. (2004). Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 9931002.
  • Brink M, Wellen J, Delafontaine P (1996). Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 97: 25092516.
  • Bustin SA (2002). Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 29: 2339.
  • Cabassi A, Coghi P, Govoni P, Barouhiel E, Speroni E, Cavazzini S et al. (2005). Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat. J Clin Endocrinol Metab 90: 28882897.
  • Cameron OG, Kronfol Z, Greden JF, Carroll BJ (1984). Hypothalamic-pituitary-adrenocortical activity in patients with diabetes mellitus. Arch Gen Psychiatry 41: 10901095.
  • Campbell DJ, Duncan AM, Kladis A, Harrap SB (1995). Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats. J Cardiovasc Pharmacol 26: 426436.
  • Carter CS, Cesari M, Ambrosius WT, Hu N, Diz D, Oden S et al. (2004). Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. J Gerontol A Biol Sci Med Sci 59: 416423.
  • Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M et al. (2005). PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46: 137143.
  • Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H, Akana SF (2004). Minireview: glucocorticoids-food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 145: 26332638.
  • Derosa G, Fogari E, D'Angelo A, Cicero AF, Salvadeo SA, Ragonesi PD et al. (2007). Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 32: 261268.
  • Dupuis F, Atkinson J, Liminana P, Chillon JM (2005). Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats. J Hypertens 23: 10611066.
  • Elliott WJ, Meyer PM (2007). Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201207.
  • Engeli S, Negrel R, Sharma AM (2000). Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35: 12701277.
  • Filipovsky J, Ducimetiere P, Eschwege E, Richard JL, Rosselin G, Claude JR (1996). The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. J Hypertens 14: 229235.
  • Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E et al. (2005). Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 28: 209214.
  • Friedman JM, Halaas JL (1998). Leptin and the regulation of body weight in mammals. Nature 395: 763770.
  • Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W et al. (2001). AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 298: 6270.
  • He H, Yang D, Ma L, Luo Z, Ma S, Feng X et al. (2010). Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-{delta}-dependent pathways. Hypertension 55: 869879.
  • Jöhren O, Dendorfer A, Dominiak P, Raasch W (2007). Gene expression of mineralocorticoid and glucocorticoid receptors in the limbic system is related to type-2 like diabetes in leptin-resistant rats. Brain Res 1184: 160167.
  • Kajioka T, Miura K, Kitahara Y, Yamagishi S (2007). Potential utility of combination therapy with nateglinide and telmisartan for metabolic derangements in Zucker Fatty rats. Horm Metab Res 39: 889893.
  • Kamari Y, Harari A, Shaish A, Peleg E, Sharabi Y, Harats D et al. (2008). Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats. Hypertens Res 31: 135140.
  • Keller-Wood M, Kimura B, Shinsako J, Phillips MI (1986). Interaction between CRF and angiotensin II in control of ACTH and adrenal steroids. Am J Physiol 250: R396R402.
  • de Kloet AD, Krause EG, Woods SC (2010). The renin angiotensin system and the metabolic syndrome. Physiol Behav 100: 525534.
  • Ko SH, Kwon HS, Kim SR, Moon SD, Ahn YB, Song KH et al. (2004). Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun 316: 114122.
  • Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R (2006). Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 14: 336341.
  • Larsen TM, Toubro S, Astrup A (2003). PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 27: 147161.
  • Li YQ, Ji H, Zhang YH, Ding DY, Ye XL (2006). Metabolic effects of telmisartan in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 373: 264270.
  • Ludvik B, Kueenburg E, Brunnbauer M, Schernthaner G, Prager R (1991). The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension. J Cardiovasc Pharmacol 18 (Suppl. 2): S157S159.
  • Madala HV, Tiwari S, Riazi S, Hu X, Ecelbarger CM (2008). Chronic candesartan alters expression and activity of NKCC2, NCC, and ENaC in the obese Zucker rat. Am J Physiol Renal Physiol 294: F1222F1231.
  • Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR et al. (2001). A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 21662170.
  • McGrath BP, Matthews PG, Louis W, Howes L, Whitworth JA, Kincaid-Smith PS et al. (1990). Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 16: 831838.
  • Miesel A, Müller H, Thermann M, Heidbreder M, Dominiak P, Raasch W (2010). Overfeeding-induced obesity in spontaneously hypertensive rats: an animal model of the human metabolic syndrome. Ann Nutr Metab 56: 127142.
  • Mori Y, Itoh Y, Tajima N (2007). Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 24: 146153.
  • Müller H, Schweitzer N, Jöhren O, Dominiak P, Raasch W (2007). Angiotensin II stimulates the reactivity of the pituitary-adrenal axis in leptin-resistant Zucker rats, thereby influencing the glucose utilization. Am J Physiol Endocrinol Metab 293: E802E810.
  • Müller H, Kröger J, Jöhren O, Szymczak S, Bader M, Dominiak P et al. (2010). Stress sensitivity is increased in transgenic rats with low brain angiotensinogen. J Endocrinol 204: 8592.
  • Müller-Fielitz H, Markert A, Wittmershaus C, Pahlke F, Jöhren O, Raasch W (2011). Weight loss and hypophagia after high-dose AT(1)-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. Naunyn Schmiedebergs Arch Pharmacol 383: 373384.
  • Munoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE (2009). Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 27: 24092420.
  • Nagel JM, Tietz AB, Goke B, Parhofer KG (2006). The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 55: 11491154.
  • Pavlatou MG, Mastorakos G, Lekakis I, Liatis S, Vamvakou G, Zoumakis E et al. (2008). Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. Stress 11: 6272.
  • Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: San Diego.
  • Raasch W, Bartels T, Schwartz C, Häuser W, Rütten H, Dominiak P (2002). Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors? J Hypertens 20: 24952504.
  • Raasch W, Wittmershaus C, Dendorfer A, Voges I, Pahlke F, Dodt C et al. (2006). Angiotensin II inhibition reduces stress sensitivity of hypothalamo-pituitary-adrenal axis in SHR. Endocrinology 147: 35393546.
  • Rong X, Li Y, Ebihara K, Zhao M, Aini W, Kusakabe T et al. (2009). An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice. J Pharmacol Exp Ther 331: 10961103.
  • Russell JC, Kelly SE, Schäfer S (2004). Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat. J Cardiovasc Pharmacol 44: 258265.
  • Saavedra JM, Benicky J (2007). Brain and peripheral angiotensin II play a major role in stress. Stress 10: 185193.
  • Sanchez RA, Masnatta LD, Pesiney C, Fischer P, Ramirez AJ (2008). Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens 26: 23932398.
  • Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004). Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 20542057.
  • Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S et al. (2005). Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54: 34423452.
  • Sebekova K, Lill M, Boor P, Heidland A, Amann K (2009). Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system. Am J Nephrol 29: 164170.
  • Shibasaki Y, Mori Y, Tsutumi Y, Masaki H, Sakamoto K, Murasawa S et al. (1999). Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol 51: 8391.
  • Shimabukuro M, Tanaka H, Shimabukuro T (2007). Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25: 841848.
  • Skurk T, van Hamelen V, Blum WF, Hauner H (2005). Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res 13: 969973.
  • de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D et al. (2001). Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50: 18631871.
  • Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW (2006). Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 10031009.
  • Sugimoto K, Kazdova L, Qi NR, Hyakukoku M, Kren V, Simakova M et al. (2008). Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J Hypertens 26: 12091215.
  • Thermann M, Müller-Fielitz H, Raasch W (2011). Prevention of leptin resistance by AT1-blockade. Naunyn Schmiedebergs Arch Pharmacol 383 (Suppl. 1): 33.
  • Uresin Y, Erbas B, Ozek M, Ozkok E, Gurol AO (2004). Losartan may prevent the elevation of plasma glucose, corticosterone and catecholamine levels induced by chronic stress. J Renin Angiotensin Aldosterone Syst 5: 9396.
  • Usui I, Fujisaka S, Yamazaki K, Takano A, Murakami S, Yamazaki Y et al. (2007). Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 77: 210214.
  • Velkoska E, Warner FJ, Cole TJ, Smith I, Morris MJ (2010). Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat. Nutr Metab Cardiovasc Dis 20: 4955.
  • Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M et al. (2005). Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4: 6.
  • Weiland F, Verspohl EJ (2008). Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes. Horm Metab Res 40: 760766.
  • Weisinger RS, Stanley TK, Begg DP, Weisinger HS, Spark KJ, Jois M (2009). Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 98: 192197.
  • Wienen W, Richard S, Champeroux P, Audeval-Gerard C (2001). Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin Angiotensin Aldosterone Syst 2: 3136.
  • Ye JM, Tid-Ang J, Turner N, Zeng XY, Li HY, Cooney GJ et al. (2011). PPARdelta agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle. Br J Pharmacol 163: 556566.
  • Younis F, Kariv N, Nachman R, Zangen S, Rosenthal T (2007). Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism. Clin Exp Hypertens 29: 419426.
  • Younis F, Stern N, Limor R, Oron Y, Zangen S, Rosenthal T (2010). Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. Metabolism 59: 12001209.
  • Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 15471559.
  • Zanchi A, Dulloo AG, Perregaux C, Montani JP, Burnier M (2007). Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab 293: E91E95.
  • Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J et al. (2006). Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 552: 112122.